Benefits of Metformin Use for Cholangiocarcinoma

Kaewpitoon, Soraya J; Loyd, Ryan A; Rujirakul, Ratana; Panpimanmas, Sukij; Matrakool, Likit; Tongtawee, Taweesak; Kootanavanichpong, Nusorn; Kompor, Ponthip; Chavengkun, Wasugree; Kujapun, Jirawoot; Norkaew, Jun; Ponphimai, Sukanya; Padchasuwan, Natnapa; Pholsripradit, Poowadol; Eksanti, Thawatchai; Phatisena, Tanida; Kaewpitoon, Natthawut

추천

검색

자료유형: 학술저널

저자정보: Kaewpitoon, Soraya J (School of Family Medicine and Community Medicine, Suranaree University of Technology) Loyd, Ryan A (School of Family Medicine and Community Medicine, Suranaree University of Technology) Rujirakul, Ratana (Suranaree University of Technology Hospital) Panpimanmas, Sukij (Suranaree University of Technology Hospital) Matrakool, Likit (Suranaree University of Technology Hospital) Tongtawee, Taweesak (Suranaree University of Technology Hospital) Kootanavanichpong, Nusorn (Faculty of Public Health, Vongchavalitkul University) Kompor, Ponthip (Faculty of Public Health, Vongchavalitkul University) Chavengkun, Wasugree (Faculty of Public Health, Vongchavalitkul University) Kujapun, Jirawoot (Faculty of Public Health, Vongchavalitkul University) Norkaew, Jun (Faculty of Public Health, Vongchavalitkul University) Ponphimai, Sukanya (Faculty of Public Health, Vongchavalitkul University) Padchasuwan, Natnapa (Faculty of Public Health, Khon Kaen University) Pholsripradit, Poowadol (Provincial Public Health Office of Nakhon Ratchasima) Eksanti, Thawatchai (Nakhon Ratchasima Rajabhat University) Phatisena, Tanida (Nakhon Ratchasima Rajabhat University) Kaewpitoon, Natthawut (Parasitic Disease Research Unit, Suranaree University of Technology)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제18호

발행연도: 2015.1

수록면: 8,079 - 8,083 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus. It is purportedly associated with a reduced risk for various cancers, mainly exerting anti-proliferation effects on various human cancer cell types, such as pancreas, prostate, breast, stomach and liver. This mini-review highlights the risk and benefit of metformin used for cholangiocarcinoma (CCA) prevention and therapy. The results indicated metformin might be a quite promising strategy CCA prevention and treatment, one mechanism being inhibition of CCA tumor growth by cell cycle arrest in both in vitro and in vivo. The AMPK/mTORC1 pathway in intrahepatic CCA cells is targeted by metformin. Furthermore, metformin inhibited CCA tumor growth via the regulation of Drosha-mediated expression of multiple carcinogenic miRNAs. The use of metformin seems to be safe in patients with cirrhosis, and provides a survival benefit. Once hepatic malignancies are already established, metformin does not offer any therapeutic potential. Clinical trials and epidemiological studies of the benefit of metformin use for CCA should be conducted. To date, whether metformin as a prospective chemotherapeutic for CCA is still questionable and waits further atttention.

#Metformin #cholangiocarcinoma #bile duct cancer #gall bladder cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!